Teva Pharmaceutical Industries Ltd. (TEVA) reaffirmed 2027 financial targets, including 30% operating profit margin, driven by growth and transformation programs. The company said its medicines franchise is on track to exceed $5 billion by 2030. AUSTEDO sales are expected to exceed $2.5 billion in sales by 2027 and exceed $3 billion by 2030.
Richard Francis, Teva's President and CEO, said: "Now, we are accelerating our growth into a leading biopharma company with a strong innovative medicines franchise and a powerhouse generics and biosimilars portfolio."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.